Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: Efficacy and mechanism of the combination of PARP and CDK4/6 inhibitors in the treatment of triple-negative breast cancer

Fig. 5

The combined treatment of olaparib and palbociclib is effective in vivo. a and b Tumour growth curves of (A) MDA-MB-436 and (B) HCC1937 xenografted NOD-SCID mice treated with olaparib (50 mg/kg/day) and palbociclib (100 mg/kg/day), either alone or in combination, for 21 days. The arrow indicates the start of treatment. c and d Representative images of immunohistochemical staining as indicated in the xenografted tumours (n ≥ 3 per treatment group) treated with olaparib and palbociclib either as single agents or in combination for 21 days. Scale bar, 200 μm. The small image inside is magnified 4 times relative to the large image. Student’s t-test; ***p < 0.001, **p < 0.01, *p < 0.05; ns, not significant. The data are presented as the means ± SEMs. Con: Control; Ola: Olaparib; Palb: Palbociclib

Back to article page